A study pitted Spravato against quetiapine extended-release, with the results showing that J&J’s product was more effective in patients with treatment-resistant major depressive disorder.
O2h Ventures and AI Fund invest in Small Pharma, as it works to complete studies for its lead program, a metabolite of ketamine as an oral anti-depressant.
Compass Pathways’ psilocybin therapy for treatment-resistant depression has received a breakthrough status to accelerate development – at a time when the incidence of mental illness is rapidly increasing.
As previously reported, researchers have determined that ketamine has potential as a treatment for patients at imminent risk for suicide, and as a therapy for treatment-resistant depression.